---
title: "Natural's Michael E. Fortin to Resign as CFO; Kenneth E. Wolf to Serve as Acting Principal Financial Officer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284941170.md"
description: "Natural's CFO Michael E. Fortin will resign effective May 15, 2026, to accept a new role at another company. Kenneth E. Wolf will serve as Acting Principal Financial and Principal Accounting Officer while the company searches for a replacement. The change is effective immediately, but the reason for Fortin's departure is due to increased responsibilities and opportunities at the new position. Details regarding the replacement process have not been disclosed."
datetime: "2026-05-01T21:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284941170.md)
  - [en](https://longbridge.com/en/news/284941170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284941170.md)
---

# Natural's Michael E. Fortin to Resign as CFO; Kenneth E. Wolf to Serve as Acting Principal Financial Officer

**Natural's Michael E. Fortin will resign as Chief Financial Officer effective May 15, 2026, and Kenneth E. Wolf will act as Principal Financial and Principal Accounting Officer while the company seeks a replacement.**

**Individual**

Michael E. Fortin

Kenneth E. Wolf

**Role**

Chief Financial Officer

President; Acting Principal Financial and Principal Accounting Officer

**Type of Change**

Resigned

Appointed (acting)

**Effective Date**

May 15, 2026

While company seeks replacement (effective immediately)

**Reason**

Accepted CFO role at another company with increased responsibilities and opportunities

Not disclosed

**Replacement Info**

Company seeking a replacement Chief Financial Officer

N/A

**Background Details**

Not disclosed

Formerly served as the Company's Chief Financial Officer; currently President

**Board/Committee Role Changes**

Not disclosed

Not disclosed

Original SEC Filing: NATURAL ALTERNATIVES INTERNATIONAL INC \[ NAII \] - 8-K - May. 01, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [NAII.US](https://longbridge.com/en/quote/NAII.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Natural Alternatives International, Inc. Announces 2026 Q3 and YTD Results | NAII Stock News](https://longbridge.com/en/news/286893119.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)